Neutralization sensitivity of HIV-1 subtype B’ clinical isolates from former plasma donors in China

Yabo Ouyang1, Jianping Sun1, Yang Huang1, Lu Lu2,3, Weisi Xu1, Xintao Hu1, Kunxue Hong1, Shibo Jiang2,3, Yiming Shao1* and Liying Ma1*

Abstract

Background: HIV-1 subtype B’ isolates have been predominantly circulating in China. Their intra- and inter-subtype neutralization sensitivity to autologous and heterologous plasmas has not been well studied.

Results: Twelve HIV-1 B’ clinical isolates obtained from patients were tested for their intra- and inter-subtype neutralization sensitivity to the neutralization antibodies in the plasmas from patients infected by HIV-1 B’ and CRF07_BC subtypes, respectively. We found that the plasmas from the HIV-1 B’-infected patients could potently neutralize heterologous viruses of subtype B’ with mean ID50 titer (1/x) of about 67, but they were not effective in neutralizing autologous viruses of subtype B’ with mean ID50 titer (1/x) of about 8. The plasmas from HIV-1 CRF07_BC-infected patients exhibited weak inter-subtype neutralization activity against subtype B’ viruses with ID50 titer (1/x) is about 22. The neutralization sensitivity of HIV-1 B’ isolates was inversely correlated with the neutralizing activity of plasmas from HIV-1 B’-infected patients (Spearman’s $r = -0.657, P = 0.020$), and with the number of potential N-glycosylation site (PNGS) in V1-V5 region (Spearman’s $r = -0.493, P = 0.034$), but positively correlated with the viral load (Spearman’s $r = 0.629, P = 0.028$). It had no correlation with the length of V1-V5 regions or the CD4+ T cell count. Virus AH259V has low intra-subtype neutralization sensitivity, it can be neutralized by 17b (IC50: 10 μg/ml) and 447-52D (IC50: 1.6 μg/ml), and the neutralizing antibodies (nAbs) in plasma AH259P are effective in neutralizing infection by the primary HIV-1 isolates with different subtypes with ID50 titers (1/x) in the range of 32–396.

Conclusions: These findings suggest that the HIV-1 subtype B’ viruses may mutate under the immune pressure, thus becoming resistant to the autologous nAbs, possibly by changing the number of PNGS in the V1-V5 region of the viral gp120. Some of primary HIV-1 isolates are able to induce both intra- and inter-subtype cross-neutralizing antibody responses.

Keywords: HIV-1 subtype B’, Clinical isolates, Neutralization sensitivity
HIV-1 subjects display various degrees of cross-reactive neutralizing activities [12,13]. The development of cross-reactive nAbs during HIV-1 infection correlates with duration of infection, higher plasma viral RNA load and lower CD4+ T cell counts [13-15].

NAbS could not eradicate the invasive virions because of the emergence of viral mutants resistant to autologous nAbs, even while retaining their ability to neutralize heterologous viruses of the same subtype (heterologous neutralization) [16,17]. Some studies revealed the mechanisms that HIV-1 escaped from nAbs through extensions of the variable loops of Env, protection of conserved regions from antibody recognition, extensive glycosylation patterns of Env, steric occlusion and conformational masking of receptor binding sites [10,16,18-20].

Envelope glycoprotein of HIV-1 is the target of nAbs, HIV-1 primary isolates can evolve over time to escape from autologous neutralization by increasing the level and/or changing the pattern of glycosylation on the viral env [21-23]. However, HIV-1 can evolve increased neutralization sensitivity to broadly neutralizing monoclonal antibodies (bNMab) and that the spectrum of neutralization capacities by bNMab can be broader when studied in longitudinal analysis [24].

Our previous study showed that the neutralizing antibody response and the prevalence of naturally occurring cross-reactive neutralizing activity in chronically HIV-1 subtype B+ infected FPDs [25]. In this study, we aimed to determine the intra- and inter-subtype neutralization sensitivity (i.e., the sensitivity of an HIV-1 subtype to the antibodies from patients infected by the same or different HIV-1 subtype, respectively) of HIV-1 B’, which may serve as a basis for designing an AIDS vaccine to prevent HIV-1 subtype B’ infection.

Results

General characteristics of the study subjects and viral subtypes

Viruses were isolated from the peripheral blood mononuclear cells (PBMCs) of 12 HIV-1-infected patients, who are FPDs from Anhui province of China. The subjects’ mean age was 40 years (30–52 years), 6 (50%) of them were woman. The mean CD4+ and CD8+ T cell counts were 289 (48–561) and 1016 (468–1937) per μl of whole blood, respectively. The mean plasma viral load (VL) was 4.95 (3.86-5.74) log10 HIV-1 RNA copies per ml.

Phylogenetic analysis of the gp120 region gene sequence confirmed that all HIV-1 isolates were HIV-1 subtype B’.

Phylogenetic analysis of the gp120 region gene sequence confirmed that all HIV-1 isolates were HIV-1 subtype B’. The phylogenetic tree showed that they were close to B.FR.HXB2 (HIV subtype B) and closer to B.CN.RL42 (Thai B’, a clade of HIV-1 B) (Figure 1). The amino acid (AA) lengths and numbers of PNGS in the V1–V5 regions were analyzed by comparing their HIV-1 gp120 sequences. The V1-V2 (67±1.6) and V4 (32±0.6) regions displayed a relative heterogeneity in lengths, whereas the V3 loop (35±0), V5 (12±0), C2 (99±0), C3 (52±0.1) and C4 (42±0.2) regions showed little length variation (Figure 2a). The number of PNGS ranged from 22 to 28 in V1–V5 regions with little change in the number of
patients with mean ID50 titers (1/x) of about 104 and 207, respectively, while their corresponding plasmas, AH1597P and AH311P, were not effective in neutralizing most of these HIV-1 B' isolates with mean ID50 titers (1/x) of about ≤ 8 and 21, respectively. In contrast, some of the isolates, such as AH259V and AH691V, had low neutralization sensitivity to most plasmas from the HIV-1 B'-infected patients, with mean ID50 titers (1/x) about ≤ 8 and 8.2, respectively. However, their corresponding plasmas (i.e., AH259P and AH691P) were effective in neutralizing most of these HIV-1 B' isolates, with mean ID50 titers (1/x) about 199 and 204, respectively (Table 1). The sensitivity of these isolates to neutralization by VRC01 [26] that a well known broadly neutralizing monoclonal antibodies (bnmAb) included as a control were studied. It is showed that the neutralization sensitivity (IC₅₀) of AH259V, AH691V and AH096V to VRC01 were more than a concentration of 10μg/ml (Table 1). The viral inter-subtype neutralization sensitivity of the HIV-1 B' isolates to the plasmas derived from 8 patients infected by HIV-1 CRF07_BC was determined. As shown in Table 2, most of the HIV-1 B' isolates displayed low inter-subtype neutralization sensitivity to the plasmas from those patients with mean ID50 titer (1/x) of about 22. All these results suggest that some viruses able to induce broad neutralizing antibody response gain machinery to protect themselves from the attack by the neutralizing antibodies.

12 plasmas from HIV-1 B'-infected patients were tested against a panel of 16 Env-pseudotyped reference viruses, including eight clade B strains (SVPB6, SVPB8, SVPB11, SVPB13, SVPB14, SVPB16, SVPB17 and SVPB19) [27], four C strains (SVPC5, SVPC10, SVPC13 and SVPC16) [28] and four A strains (HIV-Q461, HIV-Q769, HIV-Q259 and HIV-Q842) [29]. We found that clade B reference viruses were more easily neutralized by plasmas from HIV-1 subtype B' infected patients (mean ID50 titer (1/x): 91.7) as compared to clade C (mean ID50 titer (1/x): 57.0) and clade A reference viruses (mean ID50 titer (1/x): 61.8). 5 of 12 subtype B' plasma samples showed broad neutralization activity against more than 80% of reference viruses, especially, the plasma samples AH259P, AH691P and AH628P. The three plasma samples appeared high neutralization activity, whereas AH1597P failed to neutralized any of the panel of viruses tested, which was alike to the result of plasma samples against autologous or heterologous isolates from the HIV-1 B'-infected patients (Table 1 and Additional file 1: Table S1).

As shown in Table 1, 8/12 viruses (66.67%) used co-receptor CCR5 for cell entry, while the remaining four (33.33%) used both CCR5 and CXCR4. There was no difference between the R5 and R5X4 viruses in intra-subtype neutralization sensitivity (P = 0.126) or inter-subtype neutralization sensitivity (P = 0.349).
Table 1 Neutralization sensitivity of the HIV-1 B' isolates to the plasmas from HIV-1 B' infected patients

| Virus (co-receptor usage) | Neutralizing activity (ID50 titer, 1/x) of plasma from HIV-1 B' infected patients | VRC01§ IC50(μg/mL) (%) Inhibition | ADS-J1# |
|--------------------------|---------------------------------------------------------------------------------|-----------------------------------|---------|
| AH096V (RS)              |                                                                                   |                                   |         |
| AH104V (X4RS)            | 21 204 38 57 77 21 90 50 49.4 >10 63.9                                          |                                   |         |
| AH259V (RS)              | 11 119 14 12 16 20 98 28.1 1.107 46.9                                           |                                   |         |
| AH311V (X4R5)            | 22 40 214 166 38 28.1 >10 98.0                                                  |                                   |         |
| AH374V (X4R5)            | 19 12 19 82 50 80.9 0.081 94.2                                                   |                                   |         |
| AH968V (RS)              | 26 78 167 20 50 20 90.0 0.693 86.4                                               |                                   |         |
| AH1419V (RS)             | 78 78 10 10 38 31.8 ND 86.6                                                     |                                   |         |
| AH628V (RS)              | 10 10 148 112 38 31.8 ND 86.6                                                    |                                   |         |
| AH634V (RS)              | 140 65 120 20 263 55.3 ND 83.0                                                   |                                   |         |
| AH691V (RS)              | 14 50 474 88 38 14.0 <10                                                      |                                   |         |
| AH1188V (X4R5)           | 14 50 275 21 10 8.2 >10 81.3                                                   |                                   |         |
| AH1597V (RS)             | 20 35 275 21 10 8.2 >10 81.3                                                   |                                   |         |
| Mean                     | 143 274 207.3 103.1 62.5 40.8 240 17.3 239.1 127.1 0.320 63.4                  |                                   |         |
| SF33 (X4R5)*             | 206 156 648 648 648 80 622 441 187 399 80 648                                  |                                   |         |

Panel of Env-pseudotyped viruses

| Clade B (n=8) | 28.9 48.8 103.1 28.9 82.0 102.9 84.5 143.0 61.6 359.4 36.8 91.7 |
| Clade C (n=4) | 30.5 27.5 140.5 30.5 28.3 59.0 27.5 96.0 28.3 136.0 59.5 57.0 |
| Clade A (n=4) | 283 283 280 283 56.0 33.5 109.0 146.3 26.5 123.0 42.3 61.8 |

The plasmas were tested at a series of 3-fold dilutions ranging from 1:8 to 1:648. “—” means that the neutralizing titer is ≤8. For calculation, the ID50 titers (1/x) of ≤8 and ≥648 were treated as 8 and 648, respectively. The neutralizing titers of plasmas against the autologous virus are marked in bold and italics. *A laboratory-adapted HIV-1 strain was included as a control. §VRC01 (broadly neutralizing monoclonal antibodies) was included as a control [26]. *ADS-J1 (HIV-1 entry inhibitor) at 10 μg/mL was included as a control of the HIV-1 inhibitor [30,31].
Potential correlation of neutralization sensitivity of the HIV-1 B' isolates with the clinical and gp120 features

The potential correlation between neutralization sensitivity of the HIV-1 B' isolates and the clinical features, such as CD4+ T cell count and viral load (VL), or the gp120 features, such as length of the gp120 V1-V5 sub-regions and the number of PNGS in the V1-V5 sub-regions of gp120, was analyzed with the Spearman rank order correlation test. We found that the neutralization sensitivity of the HIV-1 B' isolates was positively correlated with VL (Figure 4b; \( r = 0.629, P = 0.028 \)), but inversely correlated with the number of PNGS in the gp120 V1-V5 sub-regions (Figure 4d; \( r = -0.493, P = 0.034 \)). No significant correlation was observed between the neutralization sensitivity of the HIV-1 B' isolates and CD4+ T cell count (Figure 4a; \( r = -0.266, P = 0.404 \)) or the lengths of the gp120 V1-V5 sub-regions (Figure 4c, \( r = -0.424, P = 0.170 \)). These results suggest that the

![Figure 3](http://www.virologyj.com/content/10/1/10)

**Figure 3** Correlation between the neutralization sensitivity of the HIV-1 B' isolates and the neutralizing activity of the plasmas from HIV-1 B'-infected patients. The intra-subtype neutralization sensitivity of the HIV-1 B' isolates is inversely correlated with the neutralizing activity of the plasmas from HIV-1 B'-infected patients against these isolates. \( P \) values (two-sided) and \( r \) values are based on Spearman’s rank test.

Table 2 Neutralization sensitivity of the HIV-1 B' isolates to the plasmas from HIV-1 CRF07_BC infected patients

| Virus (co-receptor usage) | Neutralizing activity (ID50 titer, 1/x) of plasma from HIV-1 CRF07_BC infected patients | Mean |
|--------------------------|----------------------------------------------------------------------------------------|------|
| AH096V (R5)              | 10 10 28                                                                               | 11.0 |
| AH104V (X4R5)            | 13                                                                                     | 8.6  |
| AH259V (R5)              | 27                                                                                     | 10.6 |
| AH311V (X4R5)            | 368                                                                                     | 53.0 |
| AH374V (X4R5)            | 35                                                                                     | 11.4 |
| AH491V (R5)              | 35                                                                                     | 11.4 |
| AH628V (R5)              | 13                                                                                     | 8.6  |
| AH634V (R5)              | 11 18                                                                                 | 13.1 |
| AH691V (R5)              | \( \geq 648 \)                                                                          | 16.9 |
| AH1188V (X4R5)           | 20 10 29                                                                               | 18.0 |
| AH1597V (R5)             | 17                                                                                     | 18.0 |
| Mean                     | 11.2 9.0 12.2 38.6 16.8 61.5 15.0 10.5                                                | 316  |
| SF330(X4R5)*             | \( \geq 648 \)                                                                         | 316  |

The plasmas were tested at a series of 3-fold dilutions ranging from 1:8 to 1:648. “—” means that the neutralizing titer is \( \leq 8 \). For calculation, the ID50 titers (1/x) of \( \leq 8 \) and \( \geq 648 \) were treated as 8 and 648, respectively. *A laboratory-adapted HIV-1 strain was included as a control.
HIV-1 B’ subtype may become resistant to the neutralizing antibodies by increasing the number of PNGS in the gp120 V1-V5 sub-regions.

Characterization of AH259V and AH259P
As mentioned above, AH259V could not be neutralized by any of the 12 plasma samples collected from the HIV-1 B’-infected patients, whereas AH259P could potentially neutralize 10 of the 11 heterologous HIV-1 B’. We then tested the neutralization sensitivity to several other known bnAbs, including F105 [32], IgG1B12 [33], 17b [34], 44752D [35] and 2F5 [36]. We found that F105, IgG1B12 and 2F5 failed to neutralize AH259V at a concentration of 50µg/ml, whereas 17b and 447-52D can neutralize AH259V with the values of 10 and 1.6µg/ml, respectively (Figure 5a). Subsequently, we tested the neutralizing activity of the plasma AH259P against several primary HIV-1 isolates of different subtypes, including 92RW002 (subtype A), 92US657 (subtype B), 93IN101 (subtype C), RU570 (subtype G), and BCF02 (group O). We observed that the nAbs in AH259P were effective in neutralizing all HIV-1 strains tested with ID50 titers (1/x) in the range of 32–396 (Figure 5b). These results suggest that although AH259V virus has low intra-subtype neutralization sensitivity, it can be neutralized by some known bnmAbs and the nAbs in AH259P are effective in neutralizing infection by the primary HIV-1 isolates with different subtypes. Using PL-ELISA, the epitope specificities of antibodies in AH259P were analyzed with overlapping synthetic peptides covering the sequences of the entire gp120 and both the extracellular and transmembrane domains of gp41 (data not shown). It is showed that the antibodies significantly bound to five peptides, including p27 (gp120 C2 region),
p38 (gp120 C3 region), p49 (gp120 C5 region), p64 (gp41 TM region) and p66 (gp41 TM region). However, these epitopes may not be the targets for the neutralizing antibodies since most of the neutralizing epitopes in HIV-1 Env are conformational, rather than linear [37]. Further characterization of AH259V and AH259P is warranted.

Discussion
In the present study, we evaluated the intra-subtype neutralization sensitivity of HIV-1 B’ isolates to the neutralizing antibodies in the plasmas derived from patients from whom the viruses were isolated. We demonstrated that these isolates possess high intra-subtype neutralization sensitivity to the heterologous plasmas, but very low intra-subtype neutralization sensitivity to the autologous plasmas, which is consistent with the results from our previous study on the HIV-1 CRF07_BC recombinant [38]. These findings suggest that most HIV-1 B’ viruses can induce neutralization response, but they become resistant to autologous neutralizing antibodies, most likely by the immune escape mechanism developed during disease progression. By analyzing the neutralizing activity of consecutive patient plasma against the sequentially obtained autologous virus, Arendrup et al. [39] found that the development of neutralization to the primary HIV-1 isolates was accompanied by emergence of escape virus with corresponding reduced neutralization sensitivity to autologous plasma. This may explain the apparent failure of the immune system to control HIV infection. In this study, we also showed that HIV-1 B’ isolates exhibit low inter-subtype neutralization sensitivity to the antibodies in the plasmas derived from the HIV-1 CRF07_BC-infected patients (Table 2), which may caused from low cross-reactive neutralizing activity in different subtype or the different neutralization potency in same subtype.

According to previous reports, the antibody response matures and becomes cross-neutralizing against divergent HIV-1 in up to 10% of HIV-1-infected patients, as shown in neutralization assays [40,41]. Interestingly, we found that the antibodies in some HIV-1 B’-infected patients have potent cross-neutralizing activity. 5 of 12 subtype B’ plasma samples showed broad neutralization activity against more than 80% of Env-pseudotyped reference viruses that covered HIV-1 clade B, C and A. And specially, the antibodies in AH259P could potently neutralize infection of PBMCs by a series of primary HIV-1 isolates with different subtypes (Figure 5b), while the AH259V virus was shown to be sensitive to neutralization by two known bnmAbs in this study (Figure 5a). VRC01 failed to neutralize AH259V, AH691V and AH096V at a concentration of 10μg/ml (Table 1). It is reported that many HIV-1 strains in China were resistant to PG9, PG16 and VRC01, which known to possess exceedingly high potency and breadth against diverse viruses from outside China [42]. These findings suggest that although most HIV-1 B’ viruses have low inter-subtype neutralization sensitivity, some of these primary HIV-1 isolates are able to induce both intra- and inter-subtype cross-neutralizing antibody responses.

It is reported that X4 HIV-1 viruses are generally more sensitive than R5 viruses to neutralizing antibodies [43]. Most HIV-1 B’ primary HIV-1 isolates collected from the FPDs were R5 viruses, while a few of them were dual-tropic R5X4 viruses. In our study, no significant difference in intra- and inter-subtype neutralization sensitivity between the R5 and R5X4 viruses was observed.
suggesting that these R5X4 viruses may predominantly use CCR5 co-receptor for infection.

Positive correlation was shown between neutralization sensitivity of the HIV-1 B' isolates and viral load in patients from whom the viruses were isolated, but no significant correlation between viral neutralization sensitivity and CD4+ T cell count in these patients was observed. Notably, the neutralization sensitivity of HIV-1 B' isolates is inversely correlated with neutralizing activity of plasmas from the HIV-1 B'-infected patients (Figure 3), and with the number of PNGS in the V1-V5 sub-regions of gp120 (Figure 5d). This finding agrees with the reports of others showing that the decreased neutralization sensitivity of HIV-1 isolates results from increased glycan numbers in the viral env used to build up a "glycan shield" to protect the virus from attack by neutralizing antibodies [44,45]. Interestingly, increase in the number of PNGS is generally located in the gp120 variable regions of the neutralization-resistant isolates. AH259V, for instance, has 10 PNGS in V1-V2 region, whereas other viruses (e.g., AH1597V) with less resistance have 5 PNGS in the same region.

Dhillon et al. [46] characterized the neutralization antibody present in the plasma of three individuals infected with subtype A and B viruses and found that the highly conserved neutralizing epitope in gp41 and highly variable V3 loop in gp120 may not account for the broad neutralizing activity, while the CD4 binding site in gp120 may be responsible for eliciting the neutralization antibody. We will use similar approaches to further investigate how the HIV-1 subtypes predominant in China induce intra-subtype neutralizing antibody response and protect themselves from attack by the autologous neutralizing antibodies. These studies may provide a sound scientific platform for the rational design of vaccines that induce antibody responses against the HIV-1 isolates circulating in China.

Conclusions

The results from this study indicate that the HIV-1 B' clinical isolates retain their neutralization sensitivity to the antibodies in the heterologous plasmas, but become resistant to those in autologous plasmas. Their neutralization sensitivity is inversely correlated with the neutralizing activity of nAbs from the patients infected by the same subtype of HIV-1 and with the number of PNGS in the viral gp120. The HIV-1 B' clinical isolates lack the inter-neutralization sensitivity to the neutralizing antibodies from the patients infected by the HIV-1 CRF07_BC recombinant. These findings suggest that the HIV-1 B' viruses may mutate under the immune pressure, thus becoming resistant to the autologous nAbs, possibly by changing the number of PNGS in the V1-V5 region of the viral gp120.

Methods

Study population

The study population was selected from a multicenter AIDS Cohort Study in China in 2005 and consisted of pre-selected HIV-1-infected patients, who were naive to antiretroviral therapies. All the patients had a self-reported history of paid blood donation of more than 10 years. The blood samples from 12 of these cohort patients were collected. Whole blood was used for CD4+ and CD8+ T cell counts and peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque gradient (Amersham Biosciences, Uppsala, Sweden) for HIV-1 isolation. Plasmas were separated by centrifugation from the citrated dextrose-treated blood samples and stored at −20°C until use for detection of neutralizing antibodies. We also collected plasmas from the HIV-1 CRF07_BC-infected IDUs in Xinjiang Uyghur Autonomous Region of China [38] as controls. This study was approved by the Institutional Research Ethics Community of Chinese Center for Disease Control and Prevention (IRB00002276), and all subjects signed informed consent to participate in the research study forms prior to blood and data collection.

Detection of viral load (VL), CD4+ and CD8+ T cell count

Plasma VL was measured using the HIV-1 nucleotide fluorescence quantitative assay kit (BD Biosciences, Franklin Lakes, NJ) according to the manufacturer's instructions, which has a lower detection limit (LDL) of 500 copies/ml. The average CD4+ and CD8+ T lymphocyte counts were assessed by flow cytometry analysis (BD Biosciences) [47].

Isolation of HIV-1 from patients' PBMCs

Primary HIV-1 viruses were isolated from PBMCs as previously described [39,48]. Briefly, PBMCs isolated from HIV-1-infected individuals were co-cultured with phytohemagglutinin (PHA)-stimulated PBMCs obtained from two or more HIV-1-seronegative healthy donors. The cell cultures were maintained for 4 weeks in RPMI 1640 medium (Gibco) containing 20 U/ml of recombinant interleukin-2 (IL-2), 1% penicillin and streptomycin, 2 mM glutamine, and 10% fetal bovine serum (FBS). Culture medium was changed twice a week. HIV-1 p24 was quantified using a commercial enzyme-linked immunosorbent assay (ELISA) kit (BioMerieux, France) once a week for 4 weeks. The viruses in the culture supernatants with p24 > 2 ng/ml were harvested, titrated, and stored in liquid nitrogen until used.

Amplification and genetic analysis of HIV-1 gp120 region

Viral RNA was extracted from the isolated viruses using a QIAamp® Viral RNA Mini Kit (Qiagen Inc., Chatsworth, CA) according to the manufacturer's protocol. The region coding gp120 was amplified from viral RNA
by TaKaRa’s One Step RNA PCR Kit (AMV). An outer reaction was performed with the primers ES3 (5’-GAA TAAGAGAAGACGAGA-3’, 7219–7240) and eas1 (5’-CTAGGGAGCTGGATCTTACCTTAGGTA-3’, 9005–9028). The amplification was run at 50°C for 30 min, and 94°C for 2 min followed by 40 cycles at 94°C for 30s, 62°C for 30 s (~0.3°C/cycle) and 72°C for 2 min, with a final extension of 72°C for 10 min. A nested reaction was then performed with the primers ES4 (5’-CAGAAGACAG TGGAATAAGA-3’, 7234–7254) and eas2 (5’-GCC TGTACCCTACGTTATT -3’, 8850–8870). The amplification was run for 3 cycles at 94°C for 3min, 55°C for 50s, and 72°C for 90s, then followed by 30 cycles at 94°C for 30s, 55°C for 50s and 72°C for 90s, with a final extension of 72°C for 10min (Gene Amp PCR System 9700, Applied Biosystems, Foster City, California, USA). PCR products were gel-purified by using a QIAquick Gel Extraction Kit (QIAGEN, Valencia, CA), then sequenced on an ABI 3770 Sequencer (Applied Biosciences). Chromograms were examined manually for the presence of double peaks indicative of two templates per sequencing reaction.

Sequences were aligned using GeneCutter (http://www.hiv.lanl.gov/content/sequence/GENE_CUTTER/cutter.html) and Clustal W together with selected subtypes/CRFs and then additionally edited by hand when needed. Phylogenetic analysis was performed using the neighbor-joining method in MEGA5, and the reliability of the branching orders was tested by bootstrap analysis of 1,000 replicates [49]. The length of V1 to V5 (V1-V5) in the gp120 region was analyzed using BioEdit software (version 7.1.3). Potential N-linked glycosylation sites (PNGS) in V1-V5 were predicted using the N-GLYCOSITE web tool from the Los Alamos HIV database [44].

**Determination of viral co-receptor usage**

The viral co-receptor usage of the primary HIV-1 isolates was determined as previously described [50]. Briefly, GHOST cells that express CD4 and CXCR4 (Ghost-X4) or CCR5 (Ghost-R5) were seeded in 24-well plates at the density of 1×10⁵ cells/well overnight. When about 70% confluent mono-layers, GHOST cells were infected with virus stocks (200 μ/ml) were added (Bright-Glo; Promega). Following a short incubation (minimum of 2 min), 150 μl lysis from each well was transferred to 96-well black solid plates for measurement of luminescence in a luminometer (PerkinElmer Life Sciences). Mock infected cells were used to determine background luminescence. HIV-1 Env-pseudotyped virus preparation, titration and nAbs assay in TZM-bl cells were as described previously [25]. The neutralizing activity was reported as the reciprocal of dilution (1/x) of plasma required to confer 50% inhibition (ID₅₀) of infection by the virus tested.

**Neutralization of infection by primary HIV-1 isolates in PBMCs**

The neutralizing sensitivity of A259V to the broadly neutralizing monoclonal antibodies and the neutralizing activity of A259P against primary HIV-1 isolates of different subtypes were determined as previously described [53]. PBMCs were isolated from healthy blood donor by standard density gradient centrifugation using Histopaque-1077 (Sigma Chemical Co.). The cells were placed in a 75 cm² plastic flask and incubated at 37°C for 2 hours. The non-adherent cells were collected and resuspended at 5×10⁶ in 10 ml RPMI-1640 medium containing 10% FBS, 5μg/ml PHA (Sigma) and 100 U/ml IL-2 (Sigma), followed by incubation at 37°C for 3 days. The PHA-stimulated cells were infected with corresponding primary HIV-1 isolates at 0.01 multiplicity of infection (MOI). Culture media were changed every 3 days. The supernatants were collected 10 days post-infection and tested for p24 antigen by ELISA as previously described [53]. The percentage of inhibition of p24 production and the concentration for 50% inhibition (IC₅₀) was calculated as described before [52].

**Linear antibody epitope mapping**

The linear epitopes for the antibodies in AH259P were mapped with overlapping synthetic peptides derived from the sequence of the Env of SHIVchn19 (obtained from the NIH Research and Reference Reagent Program) using PLL-ELISA as previously described [54]. Briefly, the peptides that were diluted to a concentration of
10μg/ml in PBS were added to the wells (50μl/well) coated with PLL (poly-L-leucine, 30–70 kDa, Sigma Aldrich), followed by incubation at room temperature for 1 h and washed with PBS. After addition of 1% glutaraldehyde (Sigma Aldrich), the plate was incubated at room temperature for 15 min and washed twice with PBS. The test plasma that were diluted at 1:400 in PBS containing 5% skimmed dry milk were added into the plates in duplicate and incubated at 37°C for 1 h, followed by addition of HRP-linked anti-human IgG and OPD substrate, sequentially. The OD value for each well was read with an automated plate reader at 450 nm. An OD value greater than two-fold average OD value of background was considered as positive.

Statistical analysis
Correlations between neutralization sensitivity and variables were analyzed using a Spearman’s rank test (SPSS software package, version 17.0), and a P value less than 0.05 was considered statistically significant.

Additional file

Additional file 1: Table S1. Neutralization activity of 12 plasmas against a panel of 16 Env-Pseudotyped viruses.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
LM and YS conceived and designed the experiments. YO, JS, SJ, YS, and LM analyzed the data and wrote the paper. All authors read and approved the final manuscript.

Acknowledgements
We are grateful to the AIDS Research and Reference Reagent Program, NIH, for providing TZM-bl cells, peptides, broadly neutralizing monoclonal antibodies, Ghost cell lines and primary HIV strains. We also acknowledge NIAID, NIH, for providing TZM-bl cells, peptides, broadly neutralizing monoclonal antibodies. We are grateful to W. Li and H. Liu for providing autologous neutralizing antibodies in human immunodeficiency virus type 1 infection. We are grateful to Y. Guo and XH performed the experiments. YO, JS, SJ, YS, and LM analyzed the data and wrote the paper. All authors read and approved the final manuscript.

Author details
1 State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China-CDC), Beijing 102206, China. 2 Key Laboratory of Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai 200032, China. 3 Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA.

Received: 5 March 2012 Accepted: 27 December 2012
Published: 5 January 2013

References
1. Kalish ML, Luo CC, Weniger BG, Limpakarnjanarat K, Young N, Ou CY, Schochetman G. Early HIV type 1 strains in Thailand were not responsible for the current epidemic. AIDS Res Hum Retroviruses 1994, 10:1573–1575.
2. Weniger BG, Takebe Y, Ou CY, Yamazaki S. The molecular epidemiology of HIV in Asia. AIDS 1994, 8(Suppl 2):S13–S28.
3. Lu L, Jia M, Ma Y, Yang L, Chen Z, Ho OD, Jiang Y, Zhang L. The changing face of HIV in China. Nature 2008, 455:S69–S61.
4. Ministry of Health, People’s Republic of China Joint United Nations Programme on HIV/AIDS World Health Organization: Estimates for the HIV/AIDS epidemic in China: Ministry of Health of the People’s Republic of China; 2009. http://www.unaids.org.cn/download/200908/China%25E2%2580%2592Estimation%25E2%2580%2593ReportEn.pdf.
5. Graf M, Shao Y, Zhao Q, Seid T, Kosterl J, Wolf H, Wagner R. Cloning and characterization of a virtually full-length HIV type 1 genome from a subtype B-Thai strain representing the most prevalent B-clade isolate in China. AIDS Res Hum Retroviruses 1998, 14:285–288.
6. Deng X, Liu H, Shao Y, Rayner S, Yang R. The epidemic origin and molecular properties of B: a founder strain of the HIV-1 transmission in Asia. AIDS 2008, 22:1851–1858.
7. Psarisiolp S, McCutchan FE, Carr JK, Sanders-Buell E, Liu W, Chen I, Wagner R, Wolf H, Shao Y, Lamb S, et al. A recent outbreak of human immunodeficiency virus type 1 infection in southern China was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant. J Virol 2009, 74:11286–11295.
8. Su L, Graf M, Zhang Y, von Briesen H, Xing H, Kosterl J, Meld H, Wolf H, Shao Y, Wagner R. Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intasubtype C/B recombinant strain in China. J Virol 2000, 74:11367–11376.
9. OuYang Y, Shao Y, Ma L. HIV-1 CRF BC recombinants infection in China: molecular epidemi and characterizations. Curr HIV Res 2012, 10:151–161.
10. Burton DR, Diesoros RC, Doms RW, Koff WC, Kwong PO, Moore JP, Nabel GJ, Sodroski J, Wilson IA, Wyatt RT. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004, 5:233–236.
11. Richman DD, Win T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003, 100:4144–4149.
12. Doria-Rose NA, Klein RM, Daniels MG, O’Dea S, Nacon M, Lapedes A, Bhattacharya T, Miguelés SA, Wyatt RT, Korber BT. Others. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol 2010, 84:1631–1636.
13. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S, Stamatatos L. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 2009, 83:767–769.
14. van Gils ML, Euler Z, Schweighardt B, Win T, Schuttemaker H. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS 2009, 23:2405–2414.
15. Euler Z, van Gils ML, Bunnik EM, Phung P, Schweighardt B, Win T, Schuttemaker H. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis 2010, 201:1045–1053.
16. Kwong PO, Doyle MW,enger DJ, Cicca C, Leavitt SA, Majeed S, Schweighardt B, Wrin T, Schuttemaker H. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 2007, 81:6178–6196.
17. Labrijn AF, Poignant P, Raja A, Zwick MB, Delgado K, Franti M, Binley J, Yvon A, Grunender C, Huang CC, et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003, 77:10557–10565.
18. Pantophlet R, Burton DR. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 2006, 24:739–769.
19. Moore PL, Gray ES, Choe JA, Ranchobe N, Mlisana K, Karim A, Salim S, Williamson C, Morris L. Others: The c3V4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol 2008, 82:1860–1869.
23. Teeraputon S, Louisirinchanakul S, Nuevarakul P: N-linked glycosylation in C2 region of HIV-1 envelope reduces sensitivity to neutralizing antibodies. Viral Immunol 2005, 18:343–353.

24. Haldar B, Burda S, Williams C, Heyndrickx L, Vanham G, Gorny MK, Nyambi P: Longitudinal study of primary HIV-1 isolates in drug-naive individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies. PLoS One 2011, 6:e17253.

25. Hu X, Hong K, Zhao C, Zheng Y, Ma L, Ruan Y, Gao H, Greene K, Sarzotti-Kelsoe M, Montefiori DC, Shai Y: Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B- infected former plasma donors from China naive to antiretroviral therapy. J Gen Virol 2012, 93:2267–2278.

26. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Do Kwon Y, Scheid JF, Shi W, Xu L, Others: Structural basis for broad and potnet neutralization of HIV-1 by antibody VRC01. Science 2010, 329:811–817.

27. Li M, Gao F, Mascara JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, et al: Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005, 79:10198–10125.

28. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, et al: Genetic and neutralization subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 2006, 80:11776–11790.

29. Bisel CA, Nedelice R, Mandalaka K, Mosier DE, Overbaugh J: HIV-1 subtype B env variable regions from early infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 2007, 21:969–722.

30. Debnath AK, Radigan L, Jiang S: Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the neutralizing epitope of the gp41 core structure of the human immunodeficiency virus type 1. J Med Chem 1999, 42:5303–5309.

31. Wang H, QZ, Guo A, Mao Q, Lu H, An X, Xia C, Li X, Debnath AK, Wu S, et al: ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation. Antimicrob Agents Chemother 2009, 53:4978–4988.

32. Posner MR, Cavacini LA, Ernes CL, Power J, Byrn R: Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J Acquir Immune Defic Syndr 1993, 6:7–14.

33. Barbos CR, Björling E, Chodli F, Dunlop N, Cabala D, Jones TM, Zebedee SL, Persson MA, Nara PL, Norry E, et al: Antibodies to several conformation-dependent epitopes of gp120/gp41 of human immunodeficiency virus type 1. Virology 1994, 68:6994–7000.

34. Zhang W, Goddillar AP, Wyatt R, Sodroski J, Chaklan B: Antibody 17b binding at the co-receptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4. Biochemistry 2001, 40:16622–1670.

35. Conley AJ, Gorny MK, Kessler JN, Boots LJ, Osipova HK, Haldar B, Schols D, De Clercq E, Fenyo EM: Variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 2004, 14:1229–1246.

36. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, et al: Antibody neutralization and escape by HIV-1. Nature 2003, 422:307–312.

37. Hidari K, Duke T, Piantanida R, Johnson WE, Decker JM, Shaw GM, Lee FH, Richman DD, Doms RW, Vanham G, Burton DR: Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infectected donors. J Virol 2007, 81:6548–6562.

38. Mandy JF, Nicholson JK, McDougall JS: Guidelines for performing single-platform absolute CD4+ T-cell determinations with CD4 gating for persons infected with human immunodeficiency virus. Centers for disease control and prevention. MMWR Recomm Rep 2003, 52:1–13.

39. van der Kaay AL, Kozaczynska K, Arien KK, Gali Y, Balazs VR, Decker SJ, Zorongrader F, Vanham G, B kerhout B, Comelli nsen M: Analysis of infectious virus clones from two HIV-1 superinfection cases suggests that the primary strains have lower fitness. Retrovirology 2010, 7:50.

40. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S: MEGAS: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011, 28:2711–2719.

41. Donners H, Willems B, Beimant E, Colebunders R, Davis D, van der Groen G: Cross-neutralizing antibodies against primary isolates in African women infected with HIV-1. AIDS 2002, 16:501–503.

42. Jiang S, Lu H, Zhao Q, He Y, Shattock R, Neurath AR, Jiang BS: Neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in China. J Biol Chem 2011, 286:14531–14541.

43. Hei FX, Tang HL, Hong KK, Chen JP, Peng H, Yuan L, Xu JQ, Shao YM: Association of neutralization sensitivity of HIV-1 primary isolates with biological properties of isolates from HIV-1 infected Chinese individuals. Biomed Environ Sci 2005, 18:128–136.

44. Zhang M, Gaschen B, Bay W, Foley B, Haigwood N, Kuiken C, Korber B: Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 2004, 14:1229–1246.